Skip to Content

Alaunos Therapeutics Inc TCRT

Morningstar Rating
$0.62 −0.21 (25.06%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

TCRT is trading at a 116% premium.
Price
$0.84
Fair Value
$6.93
Uncertainty
Extreme
1-Star Price
$96.29
5-Star Price
$1.78
Economic Moat
Jbqbj
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TCRT is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.83
Day Range
$0.610.83
52-Week Range
$0.617.95
Bid/Ask
$0.62 / $0.64
Market Cap
$9.96 Mil
Volume/Avg
292,260 / 43,394

Key Statistics

Price/Earnings (Normalized)
Price/Sales
147.52
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
34

Comparables

Valuation

Metric
TCRT
ACLX
CGEM
Price/Earnings (Normalized)
Price/Book Value
2.775.771.70
Price/Sales
147.5220.25
Price/Cash Flow
396.90
Price/Earnings
TCRT
ACLX
CGEM

Financial Strength

Metric
TCRT
ACLX
CGEM
Quick Ratio
3.345.3219.75
Current Ratio
4.875.4620.33
Interest Coverage
−24.07−22.10
Quick Ratio
TCRT
ACLX
CGEM

Profitability

Metric
TCRT
ACLX
CGEM
Return on Assets (Normalized)
−85.84%−1.99%−21.39%
Return on Equity (Normalized)
−124.33%−3.75%−22.60%
Return on Invested Capital (Normalized)
−96.60%−7.24%−26.73%
Return on Assets
TCRT
ACLX
CGEM
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
BjqshnndcjKzdv$631.1 Bil
Vertex Pharmaceuticals Inc
VRTX
RrrwqnxvSnlmz$120.6 Bil
Regeneron Pharmaceuticals Inc
REGN
TxwylgkbNqbzld$114.5 Bil
Moderna Inc
MRNA
BjgxrqzBrtzk$51.1 Bil
argenx SE ADR
ARGX
QhtvbswWmbv$22.6 Bil
BioNTech SE ADR
BNTX
SlqfgzcnfBnvt$20.8 Bil
Alnylam Pharmaceuticals Inc
ALNY
QrsvdtncPtqyr$19.5 Bil
Biomarin Pharmaceutical Inc
BMRN
GpfhybjxNyqty$16.0 Bil
United Therapeutics Corp
UTHR
KtgvmybtvQkqy$13.6 Bil
Incyte Corp
INCY
MmhtybjrLvycykz$12.1 Bil

Sponsor Center